Market Place
Sourcing Support
CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC
15 Nov 2024 //
GLOBENEWSWIRE
Nipocalimab Demonstrates Disease Control In Myasthenia Gravis Study
15 Oct 2024 //
GLOBENEWSWIRE
European Commission Approves Yuvanci For PAH
30 Sep 2024 //
GLOBENEWSWIRE
TALVEY & DARZALEX Show Durable Responses In Myeloma Patients
27 Sep 2024 //
GLOBENEWSWIRE
CARVYKTI Is First Therapy To Extend Survival For Multiple Myeloma
27 Sep 2024 //
GLOBENEWSWIRE
DARZALEX based quadruplet regimen receives positive CHMP
20 Sep 2024 //
GLOBENEWSWIRE
Dupixent Recommended for EU Approval by the CHMP
20 Sep 2024 //
GLOBENEWSWIRE
TAR-200 Plus Cetrelimab Improves Bladder Cancer Response
16 Sep 2024 //
GLOBENEWSWIRE
TAR-200 Shows 84% Complete Response In High-Risk Bladder Cancer
16 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Chemo Shows 49% Response In Colorectal Cancer
14 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Chemo Shows Positive OS Trend In EGFR-Mutated Lung Cancer
14 Sep 2024 //
GLOBENEWSWIRE
J&J Seeks EU Approval For Nipocalimab In Myasthenia Gravis
12 Sep 2024 //
GLOBENEWSWIRE
Prophylactic Dexamethasone Reduces Reactions In EGFR-Mutated NSCLC
10 Sep 2024 //
GLOBENEWSWIRE
RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer
08 Sep 2024 //
GLOBENEWSWIRE
EC Approves RYBREVANT For EGFR-Mutated Non-Small Cell Lung Cancer
27 Aug 2024 //
GLOBENEWSWIRE
EC Approves BALVERSA For Unresectable Or Metastatic Urothelial Carcinoma
23 Aug 2024 //
GLOBENEWSWIRE
CHMP Recommends RYBREVANT With Chemo For Advanced EGFR-Mutated NSCLC
26 Jul 2024 //
GLOBENEWSWIRE
CHMP Adopts Positive Opinion For BALVERSA To Treat Urothelial Carcinoma
28 Jun 2024 //
GLOBENEWSWIRE
RYBREVANT® With Chemotherapy Approved By European Commission For Lung Cancer
28 Jun 2024 //
GLOBENEWSWIRE
Nipocalimab Phase 3 Trial Shows Sustained Disease Control In Myasthenia Gravis
28 Jun 2024 //
GLOBENEWSWIRE
Janssen, Roche lead rankings in blood, breast, lung, and prostate cancer
21 Jun 2024 //
FIERCE PHARMA
Janssen ordered to pay $150M over false claims around HIV drugs
17 Jun 2024 //
ENDPTS
IMBRUVICA Shows 10-Year Survival Benefit In First-Line CLL
14 Jun 2024 //
GLOBENEWSWIRE
IMBRUVICA Plus Venetoclax Shows Sustained Benefit In CLL
14 Jun 2024 //
GLOBENEWSWIRE
TALVEY Shows Durable Responses In R R Multiple Myeloma
14 Jun 2024 //
GLOBENEWSWIRE
TECVAYLI Shows Durable Responses In Relapsed/Refractory Myeloma
03 Jun 2024 //
GLOBENEWSWIRE
CARVYKTI Improved PFS, Deepened Responses In High-Risk Multiple Myeloma
03 Jun 2024 //
GLOBENEWSWIRE
TAR-210 Shows 90% RFS In High-Risk, 90% Response In Intermediate NMIBC
05 May 2024 //
GLOBENEWSWIRE
TAR-200 Monotherapy >80% Response In High-Risk Bladder Cancer
03 May 2024 //
GLOBENEWSWIRE
EC Approves Carvykti for RRMM| Int`l Myeloma Foundation
22 Apr 2024 //
PRESS RELEASE
Janssen-Cilag`s Biologic Stelara (ustekinumab) Receives Approval in the U.S.
18 Mar 2024 //
FDA
Johnson & Johnson submits application to the EMA for DARZALEX
06 Mar 2024 //
GLOBENEWSWIRE
Janssen`s Biologic Tecvayli (teclistamab) Receives Approval in the U.S.
20 Feb 2024 //
FDA
Janssen`s Biologic Talvey (talquetamab-tgvs) Receives Approval in the U.S.
20 Feb 2024 //
FDA
Janssen Submits Application to EMA Seeking Approval of RYBREVANT
08 Feb 2024 //
PRESS RELEASE
Janssen-Cilag`s Talvey (talquetamab) Receives Approval in Europe
24 Nov 2023 //
EMA
Janssen-Cilag`s Biologic Rybrevant (Amivantamab) Receives Approval in Europe
01 Feb 2022 //
EMA
Additional manufacturing site for COVID-19 Vaccine Janssen
07 Oct 2021 //
EMA
FDA finalizes guidance on metastasis-free survival as an endpoint
06 Aug 2021 //
RAPS
Janssen-Cilag seeks EMA authorisation for Covid-19 vaccine candidate
17 Feb 2021 //
PHARMACEUTICAL-TECHNOLOGY
